Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05056350
Other study ID # PROICM 2020-07 VIS
Secondary ID 2020-A00955-34
Status Recruiting
Phase N/A
First received
Last updated
Start date September 13, 2021
Est. completion date August 22, 2023

Study information

Verified date August 2023
Source Institut du Cancer de Montpellier - Val d'Aurelle
Contact Jean-Pierre Bleuse
Phone 04 67 61 31 02
Email jean-pierre.bleuse@icm.unicancer.fr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The diagnosis of breast cancer and the treatments implemented have a significant impact on the professional situation. Maintaining employment and/or reintegration into working life are therefore major issues for cancer patients. This trial proposes to study the feasibility of a support/coaching program for a return to work in patients after breast cancer.


Description:

This study involves patients with breast cancer at the end of their adjuvant treatment. The aim of this study is to evaluate the feasibility of a support program for an adapted return to work of these patients. This back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops. The evolution of quality of life, psychological distress and perceptions concerning work will also be evaluated through assessments and questionnaires before (inclusion) and after the support program [1 month (+/- 7 days) and 6 months (+/- 1 month) after the final individual assessment]. The study also aims to estimate the recruitment rate in the study and to assess the satisfaction of this support program. Finally, the impact of this support program on the return to work will be described. This initial study will eventually lead to a larger research protocol on the effectiveness of the program, using a randomized controlled trial design.


Recruitment information / eligibility

Status Recruiting
Enrollment 25
Est. completion date August 22, 2023
Est. primary completion date August 22, 2023
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age =18 years - Patients cared at the Montpellier Cancer Institute (ICM) for non-metastatic breast cancer who have received adjuvant treatment (radiotherapy and/or chemotherapy) - Patient who has completed adjuvant treatment, except for hormonotherapy - Patient practicing a profession at the time of diagnosis, looking for a job or in professional retraining at the time of diagnosis - Patient expressing spontaneously or on request of the oncologist physical or psychological difficulties in the professional field - Patient wishing to be accompanied for an adapted return to her current job or for a return to a new more adapted job - Patient who signed the informed consent after informed information by her clinician Exclusion Criteria: - Metastatic breast cancer or any other cancer within the last 5 years - Patient who haven't completed herr adjuvant treatment (chemotherapy and/or radiotherapy) - Psychological condition requiring therapeutic support (objectified by the Mini International Neuropsychiatric Interview test (MINI) by identifying a Diagnostic and Statistical Manual (DSM)-IV Axis I psychiatric disorder (American Psychiatric Association, 1994) Sheehan et al., 1998) with the patient's refusal of adequate psychiatric treatment (medicated or not) at the time of inclusion in the study - Severely impaired global cognitive functioning (objectified by an adjusted score of less than 20 on the Montreal Cognitive Assessment (MoCA) test) - Physical inability to answer questionnaires

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Questionnaires
Quality of life questionnaires, work perception questionnaires, psychological distress questionnaire
back to work coaching
Back-to-work support program including an individual interview to identify patient needs and expectations, 7 coaching workshops (every 3 weeks +/- 15 days) and a final individual assessment post workshops

Locations

Country Name City State
France Institut du Cancer de Montpellier Montpellier

Sponsors (1)

Lead Sponsor Collaborator
Institut du Cancer de Montpellier - Val d'Aurelle

Country where clinical trial is conducted

France, 

References & Publications (5)

Arfi A, Baffert S, Soilly AL, Huchon C, Reyal F, Asselain B, Neffati S, Rouzier R, Hequet D. Determinants of return at work of breast cancer patients: results from the OPTISOINS01 French prospective study. BMJ Open. 2018 May 18;8(5):e020276. doi: 10.1136/bmjopen-2017-020276. — View Citation

Banning M. Employment and breast cancer: a meta-ethnography. Eur J Cancer Care (Engl). 2011 Nov;20(6):708-19. doi: 10.1111/j.1365-2354.2011.01291.x. Epub 2011 Sep 20. — View Citation

Barnes AJ, Robert N, Bradley CJ. Job attributes, job satisfaction and the return to health after breast cancer diagnosis and treatment. Psychooncology. 2014 Feb;23(2):158-64. doi: 10.1002/pon.3385. Epub 2013 Sep 3. — View Citation

de Boer AG, Verbeek JH, Spelten ER, Uitterhoeve AL, Ansink AC, de Reijke TM, Kammeijer M, Sprangers MA, van Dijk FJ. Work ability and return-to-work in cancer patients. Br J Cancer. 2008 Apr 22;98(8):1342-7. doi: 10.1038/sj.bjc.6604302. Epub 2008 Mar 18. — View Citation

Ekbladh E, Thorell LH, Haglund L. Perceptions of the work environment among people with experience of long term sick leave. Work. 2010;35(2):125-36. doi: 10.3233/WOR-2010-0964. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Patient adherence of a coaching program for an adapted return to work Assessment of the feasibility of a support program for an adapted return to work in patients with breast cancer, after their adjuvant treatment. Feasibility is defined by the proportion of patients who have adhered to the support program, with the patient attending at least 5 of the 7 proposed sessions. through study completion, an average of 1 year
Secondary Impact of the support program on the return to work Description of the impact of the support program on return to work, defined as any return to work, regardless of the number of hours worked by the patient before diagnosis. The description will be made by the number of patients with a return to work (resumption of previous activity or new professional activity) and, if applicable, at what date. At 1 month and at 6 months
Secondary Estimation of recruitment rate in the study Estimation of recruitment rate in the study by the proportion of patients agreeing to participate in the program among eligible patients At inclusion
Secondary Evolution of perceptions regarding work importance The score on a visual analog "work importance" scale, ranging from 0 to 10 (10 indicating a high level of importance). AT inclusion, at 1 month and 6 months
Secondary Evolution of Work Ability by the Work Ability Index, on a scale of 0 to 10 (10 indicating significant ability). AT inclusion, at 1 month and 6 months
Secondary Evolution of self-efficacy The self-efficacy score , obtained on the Lagerveld et al. (2010) to 11 items (with a high score indicating a high degree of self-efficacy. AT inclusion, at 1 month and 6 months
Secondary Satisfaction of the support program Satisfaction of the support program Assessment of the satisfaction of the support program by coaching. Assessment by program satisfaction score on a visual analog scale ranging from 1 to 10 (10 indicating high satisfaction) At 1 month and at 6 months
Secondary Quality of life (QoL) By the QoL score obtained on the EORTC QLQ-C30 & EORTC QLQ-BR23 questionnaires At inclusion, at 1 month and at 6 months
Secondary Evolution of the psychological distress of patients Description of the evolution of the psychological distress of patients. Measured by HADS scale (Hospital Anxiety and Depression Scale). The HADS is a 14 items questionnaire: 7 items related to anxiety and 7 items related to depression scored on a scale. Scores for items in each subscale of the HADS are summed to produce an anxiety score (HADS-A) or a depression score (HADS-D), or can be added to produce a total score corresponding to emotional distress (HADS-T). Each item is rated on a 4-point Likert scale (1 = "not at all", 2 = "a little", 3 = "quite a bit", and 4 = "very much"), for a total score ranging from 0-21 for each subscale. The entire scale (emotional distress) range from 0 to 42, with higher scores indicating more distress. At inclusion, at 1 month and at 6 months
See also
  Status Clinical Trial Phase
Recruiting NCT04681911 - Inetetamab Combined With Pyrotinib and Chemotherapy in the Treatment of HER2 Positive Metastatic Breast Cancer Phase 2
Terminated NCT04066790 - Pyrotinib or Trastuzumab Plus Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer Phase 2
Completed NCT04890327 - Web-based Family History Tool N/A
Completed NCT03591848 - Pilot Study of a Web-based Decision Aid for Young Women With Breast Cancer, During the Proposal for Preservation of Fertility N/A
Recruiting NCT03954197 - Evaluation of Priming Before in Vitro Maturation for Fertility Preservation in Breast Cancer Patients N/A
Terminated NCT02202746 - A Study to Assess the Safety and Efficacy of the VEGFR-FGFR-PDGFR Inhibitor, Lucitanib, Given to Patients With Metastatic Breast Cancer Phase 2
Active, not recruiting NCT01472094 - The Hurria Older PatiEnts (HOPE) With Breast Cancer Study
Recruiting NCT06049446 - Combining CEM and Magnetic Seed Localization of Non-Palpable Breast Tumors
Recruiting NCT06057636 - Hypnosis for Pain in Black Women With Advanced Breast Cancer: A Feasibility Study N/A
Recruiting NCT05560334 - A Single-Arm, Open, Exploratory Clinical Study of Pemigatinib in the Treatment of HER2-negative Advanced Breast Cancer Patients With FGFR Alterations Phase 2
Active, not recruiting NCT05501769 - ARV-471 in Combination With Everolimus for the Treatment of Advanced or Metastatic ER+, HER2- Breast Cancer Phase 1
Recruiting NCT04631835 - Phase I Study of the HS-10352 in Patients With Advanced Breast Cancer Phase 1
Completed NCT04307407 - Exercise in Breast Cancer Survivors N/A
Recruiting NCT03544762 - Correlation of 16α-[18F]Fluoro-17β-estradiol PET Imaging With ESR1 Mutation Phase 3
Terminated NCT02482389 - Study of Preoperative Boost Radiotherapy N/A
Enrolling by invitation NCT00068003 - Harvesting Cells for Experimental Cancer Treatments
Completed NCT00226967 - Stress, Diurnal Cortisol, and Breast Cancer Survival
Recruiting NCT06019325 - Rhomboid Intercostal Plane Block on Chronic Pain Incidence and Acute Pain Scores After Mastectomy N/A
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT06006390 - CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors Phase 1/Phase 2